3 High Yield Healthcare Giants With Consistent Dividend Growth: Johnson & Johnson, Merck, And Quest Diagnostics

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

Healthcare stocks with a proven history of steady dividend increases hold particular appeal for income-focused investors. This article spotlights three healthcare giants—Johnson & Johnson, Merck, and Quest Diagnostics—that have exemplified robust dividend growth over more than a decade and currently offer solid dividend yields of over 2%.

The CEOs of Uber and Salesforce are so impressed with this platform they put their own money behind it. Join them, invest in private credit, and earn 7-9% APY.

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is the world’s largest and most diverse healthcare firm. It researches, develops, manufactures, and sells various products, operating through two divisions: pharmaceutical and medical devices. These now represent all of the company’s sales following the divestment of the consumer business, Kenvue, in 2023.

According to Johnson & Johnson's most recent dividend announcement, it has consistently raised dividends for the past 62 years. On April 16, the company announced a 4.20% quarterly dividend increase to $1.24 per share, equal to $4.96 annually. Currently, the company's dividend yield is 3.31%.

Johnson & Johnson's annual revenue (as of March 31) is $85.60 billion. According to the company’s Q1 2024 earnings report, it generated revenues of $21.40 billion and EPS of $2.71. Revenues were almost in line with estimates, while EPS came in better than expected, driven by strong Medical Devices sales.

The company is scheduled to report its Q2 earnings on July 17. Consensus estimates for revenue and EPS currently stand at $22.30 billion and $2.70, respectively.

Merck

Merck (NYSE:MRK) is a healthcare company worldwide that makes pharmaceutical products to treat several conditions in many therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm’s immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases, human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs.

Merck has raised its dividends every year for the last 13 years. Its most recent dividend increase was at the end of last year. According to Merck’s announcement on Nov. 28, 2023, its Board of Directors hiked the quarterly dividend from $0.73 to $0.77 per share, or $3.08 annualized, with a yield of 2.41%. Merck is also one of the favorite dividend stocks of hedge funds.



As of March 31, the company's annual revenue stood at $61.40 billion. As per Merck's website, the company generated revenues of $15.80 billion and EPS of $2.07 in Q1 2024, above consensus estimates.

Its upcoming Q2 earnings report is scheduled for July 30, with Wall Street analysts expecting an EPS/revenue of $2.14/$15.80 billion.

Whole Foods' landlord has delivered a 15% net IRR for its investors since 2015. Check out the latest investment opportunities added to its platform.

Quest Diagnostics

Quest Diagnostics (NYSE:DGX) is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing, with specimens collected at its national network of roughly 2,300 patient service centers and multiple doctors’ offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trial testing, risk assessment services, and information technology solutions.

Quest Diagnostics has consistently raised its dividends every year since 2012. The most recent dividend hike was announced on Feb. 1, when the company reported its Q4 and full-year 2023 results. Quest Diagnostics' Board of Directors increased the company's quarterly dividend from $0.71 to $0.75 per share, equating to $3 annually. The current yield on the dividend stands at 2.08%.

The company's annual revenue (as of March 31) is $9.30 billion. Its upcoming quarterly earnings report is scheduled for July 23. Wall Street analysts estimate a quarterly EPS of $2.33 and revenue of $2.40 billion.

Looking For Higher-Yield Opportunities?

The current high-interest-rate environment has created an incredible opportunity for income-seeking investors to earn massive yields, but not through dividend stocks... Certain private market real estate investments are giving retail investors the opportunity to capitalize on these high-yield opportunities and Benzinga has identified some of the most attractive options for you to consider.

For instance, the Ascent Income Fund from EquityMultiple targets stable income from senior commercial real estate debt positions and has a historical distribution yield of 12.1% backed by real assets. With payment priority and flexible liquidity options, the Ascent Income Fund is a cornerstone investment vehicle for income-focused investors. First-time investors with EquityMultiple can now invest in the Ascent Income Fund with a reduced minimum of just $5,000.

Don't miss out on this opportunity to take advantage of high-yield investments while rates are high. Check out Benzinga's favorite high-yield offerings.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

This article 3 High Yield Healthcare Giants With Consistent Dividend Growth: Johnson & Johnson, Merck, And Quest Diagnostics originally appeared on Benzinga.com